Our Leadership

TransCelerate BioPharma launched in September 2012 to advance innovation in research and development (R&D), identify and solve common R&D challenges and further improve patient safety. The goal of our members, then and now, is to deliver more high quality medicines to patients.

 

While TransCelerate is not the first organization or consortium that the biopharmaceutical industry has formed to solve common challenges, it is one of the most ambitious and supported collaborations to date.

 

We have not only set goals, but we have delivered on these goals. And in one year, we have made significant strides toward our initial aim of making selected components of clinical trials more efficient, including:

  • Mobilized 10 companies to create TransCelerate; nine additional members added in 2013
  • Created a lean and functional infrastructure for the not-for-profit entity
  • Engaged multiple organizations – CTTI, SCRS, BIO, IOM, NIH, ACRO, iMi, etc.
  • Risk-Based Monitoring – Published the framework and approach for RBM; launched pilot studies for RBM across multiple member companies and therapeutic areas
  • Site Qualification & Training – Published the criteria for mutual recognition of GCP training
  • Clinical Data Standards – Supported publishing of SHARE environment; initiated two pilots for CDS in partnership with CDISC
  • Clinical Trial Comparator Network – Created network and completed first transaction of comparator drugs among member companies

 

In our second year, we will continue to work together in making progress toward key milestones and our ultimate goal of improving patient health. This year, we seek to:

  • Launch the first release of the Shared Investigator Site Portal
  • Initiate data standards development of additional therapeutic areas
  • Expand framework for site qualification recognition beyond GCP training
  • Engage the pharmaceutical industry and regulatory agencies in Japan, China and other regions
  • Initiate new projects and expanding scope on selected existing projects

 

TransCelerate has been enthusiastically welcomed and supported by the biopharmaceutical industry at large, as well as regulators, other clinical trial collaborations and the general clinical trial ecosystem.  My colleagues from the member companies of TransCelerate and I have an unwavering dedication to assessing, refining and creating processes aimed at the pre-competitive drug development environment. We appreciate the support during this first year and reaffirm our commitment to bring innovative new medicines to the public faster.

 

Dalvir Gill, PhD

Chief Executive Officer

TransCelerate BioPharma Inc.

Leadership Profiles

Chief Executive Officer

Dalvir Gill
Chief Executive Officer, TransCelerate BioPharma Inc.

Officers

Lynn Marks (Secretary)
SVP, Projects, Clinical Platforms & Sciences, GlaxoSmithKline

Chair of the Board

Briggs Morrison
EVP, Global Medicines Development, AstraZeneca

Board of Directors

Alfred Sandrock
SVP, Head of Development Sciences and CMO, Biogen Idec

Board of Directors

Corsee Sanders
SVP, Global Head of Product Development Innovation & Clinical Operations, Roche

Board of Directors

Elias Zerhouni
President of Global R&D, Sanofi

Board of Directors

Garry Neil
Global Head, R&D, Medgenics, Inc.

Board of Directors

Iris Loew-Friedrich
Executive Vice-President Biopharma Development Solutions and Chief Medical Officer, UCB

Board of Directors

Jan Lundberg
EVP of Science and Technology, Eli Lilly & Co.

Board of Directors

John Hubbard
SVP, Worldwide Head of Development Operations, Pfizer

Board of Directors

Klaus Dugi
Senior Vice President Medicine and Chief Medical Officer, Boehringer Ingelheim

Board of Directors

Patrick Vallance
President Pharmaceuticals R&D, GlaxoSmithKline

Board of Directors

Paul Stoffels
CSO, Worldwide Chairman of Pharmaceuticals, Johnson & Johnson

Board of Directors

Steven Gilman
EVP, Research & Development and Chief Scientific Officer, Cubist Pharmaceuticals

Board of Directors

Takuko Sawada
Senior Executive Officer, Executive General Manager, Global Development, Shionogi & Co., Ltd.

Board of Directors

Bernhardt Zeiher
Executive Vice President, Global Development and Therapeutic Area Head of Immunology, Infectious Disease, Transplant, Central Nervous System and Pain, Astellas

Board of Directors

David Nicholson
Senior Vice President, Actavis Global Brands Research & Development, Actavis/Forest

Board of Directors

Michael Severino
Executive Vice President, Chief Scientific Officer, AbbVie

Board of Directors

Paul Biondi
SVP R&D Operations, Bristol-Myers Squibb

Operations Committee Chair

Jonathan Zung
Vice President and Head of Global Clinical Sciences and Operations, UCB

Head of Delivery Excellence & Corp Affairs

Janice Chang
Head of Delivery Excellence & Corp Affairs, TransCelerate BioPharma, Inc.

Communications Committee Chair

Seema Kumar
VP, Enterprise Innovation and Global Health Communication, Johnson & Johnson